valproic acid has been researched along with Colonic Neoplasms in 22 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Colonic Neoplasms: Tumors or cancer of the COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid has been demonstrated to mediate cytotoxic effects against tumor cells by acting as a histone-deacetylase inhibitor." | 5.33 | Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. ( Atmaca, A; Chow, KU; Friedmann, I; Jäger, E; Weidmann, E, 2006) |
| "Four colon cancer cell lines with different phenotypes in regards to tumorigenicity, microsatellite stability and DNA mutation were used." | 1.42 | HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. ( Ji, M; Kim, DS; Kim, KB; Kim, Y; Lee, EJ; Lee, SJ; Park, SM; Sung, R, 2015) |
| "Vorinostat was equally effective in p53 wild-type and null cells, whereas entinostat was less effective in p53 null cells." | 1.40 | p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. ( Beck, JF; Becker, S; Krämer, OH; Marx, C; Palani, CD; Sonnemann, J; Wittig, S, 2014) |
| " The abovementioned activity of VPA as a differentiation agent suggested that it might be worth investigating its possible therapeutic potential in synergistic combination with FTS." | 1.37 | Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. ( Biran, A; Brownstein, M; Haklai, R; Kloog, Y, 2011) |
| "Interestingly, treating pancreatic and colon cancer cells with valproic acid (VPA, 2-propylpentanoic acid), a known histone deacetylase (HDAC) inhibitor, leads to up-regulation of GRP78, an endoplasmic reticulum chaperone immunoglobulin-binding protein." | 1.36 | Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. ( Bayer, TA; Iffland, L; Rossner, C; Schweyer, S; Tamboli, IY; Venkataramani, V; Walter, J; Wirths, O, 2010) |
| "Valproic acid (VPA) is a HDAC inhibitor used for the treatment of epilepsy." | 1.35 | Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. ( Boschelli, F; Cleris, L; Formelli, F; Gambacorti-Passerini, C; Magistroni, V; Mologni, L; Piazza, R, 2009) |
| "Treatment with valproic acid decreases muscle myostatin levels and enhances both follistatin expression and the inactivating phosphorylation of GSK-3beta, while these parameters are not affected by trichostatin-A." | 1.35 | Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. ( Baccino, FM; Bonelli, G; Bonetto, A; Costelli, P; Minero, VG; Penna, F; Reffo, P, 2009) |
| "Valproic acid has been demonstrated to mediate cytotoxic effects against tumor cells by acting as a histone-deacetylase inhibitor." | 1.33 | Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. ( Atmaca, A; Chow, KU; Friedmann, I; Jäger, E; Weidmann, E, 2006) |
| " However, due to its poor bioavailability in vivo, the therapeutic use of butyrate is limited." | 1.32 | Modulation of angiogenesis-related protein synthesis by valproic acid. ( Becker, U; Loitsch, S; Stein, J; Zgouras, D, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 11 (50.00) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Gabano, E | 1 |
| Gariboldi, MB | 1 |
| Marras, E | 1 |
| Barbato, F | 1 |
| Ravera, M | 1 |
| Sanaei, M | 2 |
| Kavoosi, F | 2 |
| Behjoo, H | 1 |
| Halaburková, A | 1 |
| Jendželovský, R | 1 |
| Kovaľ, J | 1 |
| Herceg, Z | 1 |
| Fedoročko, P | 1 |
| Ghantous, A | 1 |
| Patel, MM | 1 |
| Patel, BM | 1 |
| Mansoori, O | 1 |
| Ghecham, A | 1 |
| Senator, A | 1 |
| Pawlowska, E | 1 |
| Bouafia, W | 1 |
| Błasiak, J | 1 |
| Sonnemann, J | 1 |
| Marx, C | 1 |
| Becker, S | 1 |
| Wittig, S | 1 |
| Palani, CD | 1 |
| Krämer, OH | 1 |
| Beck, JF | 1 |
| Ji, M | 1 |
| Lee, EJ | 1 |
| Kim, KB | 1 |
| Kim, Y | 1 |
| Sung, R | 1 |
| Lee, SJ | 1 |
| Kim, DS | 1 |
| Park, SM | 1 |
| Sun, R | 1 |
| Zhang, S | 1 |
| Hu, W | 1 |
| Lu, X | 1 |
| Lou, N | 1 |
| Yang, Z | 1 |
| Chen, S | 1 |
| Zhang, X | 1 |
| Yang, H | 1 |
| R, M | 1 |
| P, HA | 1 |
| Mahadevan, V | 1 |
| Jones, J | 1 |
| Bentas, W | 1 |
| Blaheta, RA | 1 |
| Makarevic, J | 1 |
| Hudak, L | 1 |
| Wedel, S | 1 |
| Probst, M | 1 |
| Jonas, D | 1 |
| Juengel, E | 1 |
| Mologni, L | 1 |
| Cleris, L | 1 |
| Magistroni, V | 1 |
| Piazza, R | 1 |
| Boschelli, F | 1 |
| Formelli, F | 1 |
| Gambacorti-Passerini, C | 1 |
| Bonetto, A | 1 |
| Penna, F | 1 |
| Minero, VG | 1 |
| Reffo, P | 1 |
| Bonelli, G | 1 |
| Baccino, FM | 1 |
| Costelli, P | 1 |
| Imesch, P | 2 |
| Dedes, KJ | 2 |
| Furlato, M | 1 |
| Fink, D | 2 |
| Fedier, A | 2 |
| Venkataramani, V | 1 |
| Rossner, C | 1 |
| Iffland, L | 1 |
| Schweyer, S | 1 |
| Tamboli, IY | 1 |
| Walter, J | 1 |
| Wirths, O | 1 |
| Bayer, TA | 1 |
| Biran, A | 1 |
| Brownstein, M | 1 |
| Haklai, R | 1 |
| Kloog, Y | 1 |
| Papi, A | 1 |
| Ferreri, AM | 1 |
| Guerra, F | 1 |
| Orlandi, M | 1 |
| Zgouras, D | 1 |
| Becker, U | 1 |
| Loitsch, S | 1 |
| Stein, J | 1 |
| Naldi, M | 1 |
| Andrisano, V | 1 |
| Fiori, J | 1 |
| Calonghi, N | 1 |
| Pagnotta, E | 1 |
| Parolin, C | 1 |
| Pieraccini, G | 1 |
| Masotti, L | 1 |
| Huang, X | 1 |
| Guo, B | 1 |
| Friedmann, I | 1 |
| Atmaca, A | 1 |
| Chow, KU | 1 |
| Jäger, E | 1 |
| Weidmann, E | 1 |
| Von Bueren, AO | 1 |
22 other studies available for valproic acid and Colonic Neoplasms
| Article | Year |
|---|---|
Platinum(IV) combo prodrugs containing cyclohexane-1
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; Diamines; Histone Deacety | 2023 |
Effect of valproic acid and zebularine on SOCS-1 and SOCS-3 gene expression in colon carcinoma SW48 cell line.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Colonic Neoplasms; | 2020 |
Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Topics: Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Chromatin; Colonic Neoplasms; Cyclin-Dependent | 2017 |
Repurposing of sodium valproate in colon cancer associated with diabetes mellitus: Role of HDAC inhibition.
Topics: Animals; Anticonvulsants; Blood Glucose; Carcinoembryonic Antigen; Cell Line, Tumor; Colon; Colonic | 2018 |
Effect of valproic acid in comparison with vorinostat on cell growth inhibition and apoptosis induction in the human colon cancer SW48 cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neopl | 2018 |
Epigenetic modifiers 5-aza-2'-deoxycytidine and valproic acid differentially change viability, DNA damage and gene expression in metastatic and non-metastatic colon cancer cell lines.
Topics: Caco-2 Cells; Cell Cycle Checkpoints; Cell Survival; Checkpoint Kinase 1; Colonic Neoplasms; Cyclin- | 2019 |
p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors.
Topics: Benzamides; Cell Proliferation; Colonic Neoplasms; Flow Cytometry; Gene Expression Regulation, Neopl | 2014 |
HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells.
Topics: Cadherins; Carcinoma; Cell Movement; Colonic Neoplasms; Epithelial-Mesenchymal Transition; HCT116 Ce | 2015 |
Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Topics: Adenocarcinoma; Animals; Binding Sites; Cachexia; Carcinoma, Lewis Lung; CCAAT-Enhancer-Binding Prot | 2016 |
HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells.
Topics: Benzamides; Butyric Acid; Cell Survival; Colonic Neoplasms; Computer Simulation; DNA Methylation; Ep | 2018 |
Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Topics: Cell Adhesion; Cell Proliferation; Cells, Cultured; Colonic Neoplasms; Down-Regulation; Enzyme Inhib | 2008 |
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.
Topics: Acetylation; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2009 |
Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice.
Topics: Animals; Cachexia; Colonic Neoplasms; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme I | 2009 |
MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Colonic Neoplasms; Drug Resis | 2009 |
Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein.
Topics: Amyloid beta-Protein Precursor; Anticonvulsants; Cell Proliferation; Colonic Neoplasms; Down-Regulat | 2010 |
Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Blotting, Wes | 2011 |
Anti-invasive effects and proapoptotic activity induction by the rexinoid IIF and valproic acid in combination on colon cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Ca | 2012 |
Modulation of angiogenesis-related protein synthesis by valproic acid.
Topics: Blotting, Western; Butyrates; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Cysteine Endopeptid | 2004 |
Histone proteins determined in a human colon cancer by high-performance liquid chromatography and mass spectrometry.
Topics: Acetylation; Butyrates; Chromatography, High Pressure Liquid; Colonic Neoplasms; Histone Deacetylase | 2006 |
Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells.
Topics: Adenomatous Polyposis Coli Protein; Apoptosis; beta Catenin; Colonic Neoplasms; Down-Regulation; Enz | 2006 |
Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; | 2006 |
The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamil | 2007 |